Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-19-000057
Filing Date
2019-11-12
Accepted
2019-11-12 16:57:32
Documents
43
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vrml-20190930x10q.htm 10-Q 1285145
2 EX-31.1 vrml-20190930xex31_1.htm EX-31.1 15370
3 EX-31.2 vrml-20190930xex31_2.htm EX-31.2 15812
4 EX-32.1 vrml-20190930xex32_1.htm EX-32.1 12098
5 GRAPHIC vrml-20190930x10qg001.jpg GRAPHIC 6840
  Complete submission text file 0000926617-19-000057.txt   3764713

Data Files

Seq Description Document Type Size
6 EX-101.INS vrml-20190930.xml EX-101.INS 635591
7 EX-101.SCH vrml-20190930.xsd EX-101.SCH 29304
8 EX-101.CAL vrml-20190930_cal.xml EX-101.CAL 31090
9 EX-101.DEF vrml-20190930_def.xml EX-101.DEF 100009
10 EX-101.LAB vrml-20190930_lab.xml EX-101.LAB 236637
11 EX-101.PRE vrml-20190930_pre.xml EX-101.PRE 189466
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 191210513
SIC: 2835 In Vitro & In Vivo Diagnostic Substances